Ji Yun Noh

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1696884/publications.pdf

Version: 2024-02-01

	331670	345221
1,733	21	36
citations	h-index	g-index
90	90	3251
docs citations	times ranked	citing authors
	citations 90	1,733 21 citations h-index 90 90

#	Article	IF	CITATIONS
1	Clinical Significance of a High SARS-CoV-2 Viral Load in the Saliva. Journal of Korean Medical Science, 2020, 35, e195.	2.5	232
2	Comparison of the second and third waves of the COVID-19 pandemic in South Korea: Importance of early public health intervention. International Journal of Infectious Diseases, 2021, 104, 742-745.	3.3	138
3	Asymptomatic infection and atypical manifestations of COVID-19: Comparison of viral shedding duration. Journal of Infection, 2020, 81, 816-846.	3.3	105
4	SARS-CoV-2 mutations, vaccines, and immunity: implication of variants of concern. Signal Transduction and Targeted Therapy, 2021, 6, 203.	17.1	65
5	Social Distancing against COVID-19: Implication for the Control of Influenza. Journal of Korean Medical Science, 2020, 35, e182.	2.5	54
6	Clinical and microbiological characterization of carbapenem-resistant Acinetobacter baumannii bloodstream infections. Journal of Medical Microbiology, 2011, 60, 605-611.	1.8	49
7	Effects of influenza immunization on pneumonia in the elderly. Human Vaccines and Immunotherapeutics, 2018, 14, 744-749.	3.3	48
8	Long-term immunogenicity and safety of inactivated Hantaan virus vaccine (Hantavaxâ,,¢) in healthy adults. Vaccine, 2016, 34, 1289-1295.	3.8	45
9	Colistin and rifampicin combination in the treatment of ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii. International Journal of Antimicrobial Agents, 2008, 32, 281-284.	2.5	39
10	Safe hospital preparedness in the era of COVID-19: The Swiss cheese model. International Journal of Infectious Diseases, 2020, 98, 294-296.	3.3	38
11	The Korean Influenza National Immunization Program: History and Present Status. Infection and Chemotherapy, 2017, 49, 247.	2.3	37
12	Seroprevalence of Anti-SARS-CoV-2 Antibodies among Outpatients in Southwestern Seoul, Korea. Journal of Korean Medical Science, 2020, 35, e311.	2.5	31
13	Incidence and case fatality rates of community-acquired pneumonia and pneumococcal diseases among Korean adults: Catchment population-based analysis. PLoS ONE, 2018, 13, e0194598.	2.5	29
14	Immunogenicity of trivalent influenza vaccines in patients with chronic kidney disease undergoing hemodialysis: MF59-adjuvanted versus non-adjuvanted vaccines. Human Vaccines and Immunotherapeutics, 2016, 12, 2902-2908.	3.3	28
15	Immunogenicity and safety of concomitant MF59-adjuvanted influenza vaccine and 23-valent pneumococcal polysaccharide vaccine administration in older adults. Vaccine, 2015, 33, 4647-4652.	3.8	26
16	Viral shedding from diverse body fluids in a patient with severe fever with thrombocytopenia syndrome. Journal of Clinical Virology, 2016, 80, 33-35.	3.1	26
17	Early Safety Monitoring of COVID-19 Vaccines in Healthcare Workers. Journal of Korean Medical Science, 2021, 36, e110.	2.5	26
18	<i>In vitro</i> Comparison of Anti-Biofilm Effects against Carbapenem-Resistant <i>Acinetobacter baumannii</i> Imipenem, Colistin, Tigecycline, Rifampicin and Combinations. Infection and Chemotherapy, 2015, 47, 27.	2.3	25

#	Article	IF	CITATIONS
19	Cost-effectiveness of pneumococcal vaccination strategies for the elderly in Korea. PLoS ONE, 2017, 12, e0177342.	2.5	25
20	Longitudinal Assessment of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Immune Responses for Six Months Based on the Clinical Severity of Coronavirus Disease 2019. Journal of Infectious Diseases, 2021, 224, 754-763.	4.0	24
21	Effectiveness of Pneumococcal Vaccination Against Pneumococcal Pneumonia Hospitalization in Older Adults: A Prospective, Test-Negative Study. Journal of Infectious Diseases, 2022, 225, 836-845.	4.0	24
22	Laboratory Surveillance of Influenza-Like Illness in Seven Teaching Hospitals, South Korea: 2011–2012 Season. PLoS ONE, 2013, 8, e64295.	2.5	24
23	A Systems Vaccinology Approach Reveals the Mechanisms of Immunogenic Responses to Hantavax Vaccination in Humans. Scientific Reports, 2019, 9, 4760.	3.3	23
24	Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine and an MF59-adjuvanted influenza vaccine after concomitant vaccination in $\hat{a} \otimes \frac{3}{4}$ 60-year-old adults. Vaccine, 2017, 35, 313-320.	3.8	22
25	Paradoxical long-term impact of maternal influenza infection on neonates and infants. BMC Infectious Diseases, 2020, 20, 502.	2.9	22
26	Clinical characteristics and disease burden of respiratory syncytial virus infection among hospitalized adults. Scientific Reports, 2020, 10, 12106.	3.3	22
27	Disease burden of 2013-2014 seasonal influenza in adults in Korea. PLoS ONE, 2017, 12, e0172012.	2.5	22
28	Influenza Vaccines: Unmet Needs and Recent Developments. Infection and Chemotherapy, 2013, 45, 375.	2.3	20
29	Prospective Cohort Study on the Effectiveness of Influenza and Pneumococcal Vaccines in Preventing Pneumonia Development and Hospitalization. Vaccine Journal, 2015, 22, 229-234.	3.1	20
30	Matrix Metalloproteinase-13 in Atherosclerotic Plaque Is Increased by Influenza A Virus Infection. Journal of Infectious Diseases, 2020, 221, 256-266.	4.0	20
31	Influenza and Pneumococcal Vaccine Coverage Rates among Patients Admitted to a Teaching Hospital in South Korea. Infection and Chemotherapy, 2015, 47, 41.	2.3	19
32	Analysis of Risk Factors for Severe Acute Respiratory Infection and Pneumonia and among Adult Patients with Acute Respiratory Illness during 2011-2014 Influenza Seasons in Korea. Infection and Chemotherapy, 2016, 48, 294.	2.3	19
33	Seroprevalence and disease burden of acute hepatitis A in adult population in South Korea. PLoS ONE, 2017, 12, e0186257.	2.5	18
34	Clinical usefulness of pneumococcal urinary antigen test, stratified by disease severity and serotypes. Journal of Infection and Chemotherapy, 2015, 21, 672-679.	1.7	17
35	Development of a multiplexed opsonophagocytic killing assay (MOPA) for group B <i>Streptococcus</i> . Human Vaccines and Immunotherapeutics, 2018, 14, 67-73.	3.3	15
36	Cost-effectiveness of influenza vaccine strategies for the elderly in South Korea. PLoS ONE, 2019, 14, e0209643.	2.5	14

#	Article	IF	CITATIONS
37	How lessons learned from the 2015 Middle East respiratory syndrome outbreak affected the response to coronavirus disease 2019 in the Republic of Korea. Korean Journal of Internal Medicine, 2021, 36, 271-285.	1.7	14
38	Viral Shedding and Environmental Cleaning in Middle East Respiratory Syndrome Coronavirus Infection. Infection and Chemotherapy, 2015, 47, 252.	2.3	13
39	Immunogenicity and safety of a split-virion quadrivalent influenza vaccine in adults 18–60Âyears of age in the Republic of Korea. Human Vaccines and Immunotherapeutics, 2018, 14, 587-592.	3.3	13
40	Spread of ceftriaxone non-susceptible pneumococci in South Korea: Long-term care facilities as a potential reservoir. PLoS ONE, 2019, 14, e0210520.	2.5	13
41	Hemorrhagic Fever with Renal Syndrome. Infection and Chemotherapy, 2019, 51, 405.	2.3	13
42	Pulmonary and psoas muscle nocardiosis in a patient with lupus nephritis: a case report and review of the literature. Rheumatology International, 2011, 31, 929-936.	3.0	12
43	Perception and Attitudes of Korean Obstetricians about Maternal Influenza Vaccination. Journal of Korean Medical Science, 2016, 31, 1063.	2.5	12
44	Polyarthralgia and Myalgia Syndrome after ChAdOx1 nCOV-19 Vaccination. Journal of Korean Medical Science, 2021, 36, e245.	2.5	12
45	Interim estimates of the effectiveness of the influenza vaccine against A(H3N2) influenza in adults in South Korea, 2016–2017 season. PLoS ONE, 2017, 12, e0178010.	2.5	12
46	Suboptimal Effectiveness of the 2011–2012 Seasonal Influenza Vaccine in Adult Korean Populations. PLoS ONE, 2015, 10, e0098716.	2.5	11
47	Perceptions of influenza vaccination during pregnancy in Korean women of childbearing age. Human Vaccines and Immunotherapeutics, 2016, 12, 1997-2002.	3.3	11
48	Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in HIV-infected adults in the era of highly active antiretroviral therapy: analysis stratified by CD4 T-cell count. Human Vaccines and Immunotherapeutics, 2020, 16, 169-175.	3.3	11
49	Skin and soft tissue infections: Experience over a five-year period and clinical usefulness of ultrasonography-guided gun biopsy-based culture. Scandinavian Journal of Infectious Diseases, 2011, 43, 870-876.	1.5	9
50	Acute Myopericarditis caused by Human Metapneumovirus. Infection and Chemotherapy, 2016, 48, 36.	2.3	9
51	Epidemiology of community-acquired pneumonia in the era of extended serotype-covering multivalent pneumococcal conjugate vaccines. Vaccine, 2020, 38, 7747-7755.	3.8	9
52	Immunogenicity and safety of a cell culture-derived inactivated quadrivalent influenza vaccine (NBP607-QIV): A randomized, double-blind, multi-center, phase III clinical trial in adults and elderly subjects. Human Vaccines and Immunotherapeutics, 2017, 13, 1653-1660.	3.3	8
53	Effectiveness of influenza and pneumococcal polysaccharide vaccines against influenza-related outcomes including pneumonia and acute exacerbation of cardiopulmonary diseases: Analysis by dominant viral subtype and vaccine matching. PLoS ONE, 2018, 13, e0207918.	2.5	8
54	Significant circulation of influenza B viruses mismatching the recommended vaccine-lineage in South Korea, 2007–2014. Vaccine, 2018, 36, 5304-5308.	3.8	8

#	Article	IF	CITATIONS
55	Pneumonitis and concomitant bacterial pneumonia in patients receiving pembrolizumab treatment. Medicine (United States), 2019, 98, e16158.	1.0	8
56	Effectiveness of repeated influenza vaccination among the elderly population with high annual vaccine uptake rates during the three consecutive A/H3N2 epidemics. Vaccine, 2020, 38, 318-322.	3.8	8
57	Comparison of antiviral effect for mild-to-moderate COVID-19 cases between lopinavir/ritonavir versus hydroxychloroquine: A nationwide propensity score-matched cohort study. International Journal of Infectious Diseases, 2021, 102, 275-281.	3.3	8
58	Immunogenicity and safety of a cell culture-derived inactivated trivalent influenza vaccine (NBP607): A randomized, double-blind, multi-center, phase 3 clinical trial. Vaccine, 2015, 33, 5437-5444.	3.8	7
59	Immunogenicity and safety of a tetanus-diphtheria vaccine and a 13-valent pneumococcal conjugate vaccine after concomitant vaccination in ≥ 50-year-old adults. BMC Infectious Diseases, 2018, 18, 62	8 ^{2.9}	7
60	Immunogenicity and safety of a modified three-dose priming and booster schedule for the Hantaan virus vaccine (Hantavax): A multi-center phase III clinical trial in healthy adults. Vaccine, 2020, 38, 8016-8023.	3.8	7
61	Persistent serotype 3 and 19A invasive pneumococcal diseases in adults in vaccine era: Serotype-dependent difference in ceftriaxone susceptibility. Vaccine, 2022, 40, 2258-2265.	3.8	7
62	Clinical performance of the Sofiaâ,,¢ Influenza A+B FIA in adult patients with influenza-like illness. Diagnostic Microbiology and Infectious Disease, 2015, 83, 130-132.	1.8	6
63	Antiviral therapy in seasonal influenza and 2009 H1N1 pandemic influenza: Korean experiences and perspectives. Expert Review of Anti-Infective Therapy, 2015, 13, 1361-1372.	4.4	6
64	Identification of influenza C virus in young South Korean children, from October 2013 to September 2016. Journal of Clinical Virology, 2019, 115, 47-52.	3.1	6
65	Coronavirus Disease 2019 Outbreak at Nightclubs and Distribution Centers after Easing Social Distancing: Vulnerable Points of Infection. Journal of Korean Medical Science, 2020, 35, e247.	2.5	6
66	Safety and Effectiveness of Peramivir in Korean Adult Influenza Patients: Prospective Observational Study Based on Post-Marketing Surveillance Data. Journal of Korean Medical Science, 2018, 33, e212.	2.5	5
67	Duration of Humoral Immunity and Cross-Neutralizing Activity Against the Alpha, Beta, and Delta Variants After Wild-Type Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Prospective Cohort Study. Journal of Infectious Diseases, 2022, 226, 975-978.	4.0	5
68	Cost-Effectiveness of Influenza Vaccination Strategies in Adults: Older Adults Aged ≥65 Years, Adults Aged 50–64 Years, and At-Risk Adults Aged 19–64 Years. Vaccines, 2022, 10, 445.	4.4	5
69	Physician Attitudes toward the Herpes Zoster Vaccination in South Korea. Infection and Chemotherapy, 2014, 46, 194.	2.3	4
70	Age-stratified analysis of serotype-specific baseline immunity against group B streptococcus. Human Vaccines and Immunotherapeutics, 2020, 16, 1338-1344.	3.3	4
71	Randomized, double-blind, multi-center, phase III clinical trial to evaluate the immunogenicity and safety of MG1109 (egg-based pre-pandemic influenza A/H5N1 vaccine) in healthy adults. Human Vaccines and Immunotherapeutics, 2017, 13, 1190-1197.	3.3	3
72	Campylobacter jejuni Bacteremia in a Liver Cirrhosis Patient and Review of Literature: A Case Study. Infection and Chemotherapy, 2017, 49, 230.	2.3	3

#	Article	IF	Citations
73	Viable SARS-CoV-2 shedding under remdesivir and dexamethasone treatment. Journal of Infection, 2022, 84, 834-872.	3.3	3
74	Clinical and microbiological characterization of serotype 6D pneumococcal infections in South Korea. Journal of Infection and Chemotherapy, 2016, 22, 515-520.	1.7	2
75	Humoral and Cellular Immunogenicity Induced by Avian Influenza A (H7N9) DNA Vaccine in Mice. Infection and Chemotherapy, 2017, 49, 117.	2.3	2
76	A comparison of epidemiology and clinical outcomes between influenza A H1N1pdm09 and H3N2 based on multicenter surveillance from 2014 to 2018 in South Korea. Influenza and Other Respiratory Viruses, 2021, 15, 99-109.	3.4	2
77	Seroepidemiologic survey of emerging vector-borne infections in South Korean forest/field workers. PLoS Neglected Tropical Diseases, 2021, 15, e0009687.	3.0	2
78	Disease Burden and Risk Factors of Hospitalized Community-Acquired Pneumonia in Korean Adults. Open Forum Infectious Diseases, 2016, 3, .	0.9	1
79	Hospital-based Influenza Morbidity and Mortality (HIMM) Surveillance for A/H7N9 Influenza Virus Infection in Returning Travelers. Journal of Korean Medical Science, 2018, 33, e49.	2.5	1
80	Randomized, single-blind, active-controlled phase I clinical trial to evaluate the immunogenicity and safety of GC3114 (high-dose, quadrivalent influenza vaccine) in healthy adults. Vaccine, 2019, 37, 5171-5176.	3.8	1
81	A Case of Disseminated Tuberculosis with Miliary Central Nervous System Tuberculoma. Infection and Chemotherapy, 2008, 40, 323.	2.3	1
82	Characteristics of Viruses and the Infection Control. Korean Journal of Healthcare-Associated Infection Control and Prevention, 2020, 25, 100-104.	0.6	1
83	Immunogenicity and Reactogenicity of Ad26.COV2.S in Korean Adults: A Prospective Cohort Study. Journal of Korean Medical Science, 2022, 37, .	2.5	1
84	Modeling Incorporating the Severity-Reducing Long-term Immunity: Higher Viral Transmission Paradoxically Reduces Severe COVID-19 During Endemic Transition. Immune Network, 2022, 22, .	3.6	1
85	Seroprevalence and Disease Burden of Acute Hepatitis A in Adult Population in South Korea. Open Forum Infectious Diseases, $2016, 3, \ldots$	0.9	0
86	2282. Age-Stratified Analysis of Serotype-Specific Immunity Against Group B Streptococcus. Open Forum Infectious Diseases, 2018, 5, S676-S676.	0.9	0
87	Risk factors for SARS-CoV-2 transmission in non-household clusters. Journal of Infection, 2021, 83, e22-e24.	3.3	0
88	Invasive Aspergillosis of the Paranasal Sinuses Invading Skull Base: Successful Treatment with Voriconazole. Infection and Chemotherapy, 2008, 40, 110.	2.3	0
89	Pulmonary Toxocariasis Mimicking Invasive Aspergillosis in a Patient with Ulcerative Colitis. Korean Journal of Parasitology, 2014, 52, 425-428.	1.3	0